Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jie Wang, Dr
CONTACT
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This study will explore the treatment of locally advanced or metastatic non-small cell lung cancer with HER2 mutation, amplification, or HER2 protein overexpression, using Disitamab Vedotin(RC48)combined with EGFR or HER2 TKIs, in the aim of providing new treatment strategies for lung cancer patients with HER2 pathway activation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
